1 / 9

Switch studies in virologically suppressed patients

Switch studies in virologically suppressed patients. Switch to TDF/FTC/EFV AI266-073 Switch to FTC + ddI + EFV ALIZE Switch to ATV/r-containing regimen ATAZIP Switch to ATV ± r-containing regimen SWAN SLOAT Switch to ATV-containing regimen ARIES INDUMA Switch to ATV/r monotherapy

fausta
Download Presentation

Switch studies in virologically suppressed patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Switch studies in virologically suppressed patients Switch to TDF/FTC/EFV AI266-073 Switch to FTC + ddI + EFV ALIZE Switch to ATV/r-containing regimen ATAZIP Switch to ATV±r-containing regimen SWAN SLOAT Switch to ATV-containing regimen ARIES INDUMA Switch to ATV/r monotherapy ATARITMO Swedish Study ACTG A5201 OREY Synopsis • Switch to LPV/r monotherapy • Pilot LPV/r • M03-613 • American Study • KalMo • OK • OK04 • KALESOLO • MOST • HIV-NAT 077 • Switch to DRV/r monotherapy • MONOI • MONET • Switch to RAL-containing regimen • Canadian Study • CHEER • Montreal Study • EASIER • SWITCHMRK • SPIRAL

  2. MONET Study: Switch PI or NNRTI to DRV/r qd monotherapy • Design Randomisation* 1 : 1 Open-label W48 W144 N = 129 293 HIV+ adults On 2 NRTIs + (PI or NNRTI) Darunavir-naïve No history of prior virologic failure HIV-1 RNA < 50 c/mL > 6 months N = 127 * Randomisation was stratified on the use of PI or NNRTI (57% patients on PI, 43% on NNRTI) ** NRTI used at baseline: TDF + FTC = 46% ; ABC + 3TC: 31% ; ZDV + 3TC = 10% ; TDF + 3TC = 7% ; other combinations: 6% • Objective • Non inferiority in the proportion of patients with HIV-1 RNA < 50 c/mL at W48 (per-protocol analysis, switch= failure, TLOVR algorithm) ; lower limit of the 95% CI for the difference= - 12%, 80% power Arribas J, AIDS 2010;24:223-230 MONET

  3. MONET Study: Switch PI or NNRTI to DRV/r qd monotherapy Baseline characteristics and patient disposition • At baseline, 13 patients had HIV-1 RNA levels > 50 c/mL (9 in the monotherapy arm and 4 in the triple therapy arm) despite having results < 50 c/ml at screening Arribas J, AIDS 2010;24:223-230 MONET

  4. MONET Study: Switch PI or NNRTI to DRV/r qd monotherapy HIV-1 RNA < 50 c/mL(TLOVR, switch = failure) ITT, switch-included analysis Per-protocol (primary endpoint) ITT % 95.1% 93.5% 87.8% 86.2% 85.3% 100 84.3% 75 50 25 N= 123 123 129 127 0 95% CI for the difference= - 10.1 ; 6.8 95% CI for the difference= - 9.9 ; 8.8 95% CI for the difference= - 7.4 ; 4.2 DRV/r + 2 NRTIs DRV/r qd monotherapy Results: W48 outcome • Non inferiority of DRV/r monotherapy Arribas J, AIDS 2010;24:223-230 MONET

  5. MONET Study: Switch PI or NNRTI to DRV/r qd monotherapy Outcomes of confirmed HIV RNA elevations Arribas J, AIDS 2010;24:223-230 MONET

  6. MONET Study: Switch PI or NNRTI to DRV/r qd monotherapy Outcomes of discontinuations from the trial Arribas J, AIDS 2010;24:223-230 MONET

  7. MONET Study: Switch PI or NNRTI to DRV/r qd monotherapy Other endpoints • In multivariate analysis, hepatitis C co-infection was a significant predictor of confirmed HIV RNA elevations (p < 0.01) • Resistance data: Genotype was available for 35/61 patients with HIV RNA > 50 c/mL (22 in the monotherapy group and 13 in the triple therapy group) • Resistance mutations to PI in 1 one patient in each arm, with no phenotypic resistance to DRV. HIV-1 RNA returned to < 50 c/mL without changing therapy in both patients • Most common grade 2 to 4 adverse events (AE) were gastrointestinal • Serious AE were seen in 9 patients in each group • Discontinuation for AE by W48 occurred in 8 patients in the monotherapy group and 3 in the triple therapy group • Grade 1 to 4 nervous system AE were seen in 16% of patients in each group, and Grade 1 to 4 psychiatric AE in 9% of patients in each group • There were more haematological abnormalities in the triple therapy arm,related to zidovudine Arribas J, AIDS 2010;24:223-230 MONET

  8. MONET Study: Switch PI or NNRTI to DRV/r qd monotherapy • Conclusions from W48 data • In patients with virologic suppression on standard triple therapy (2 NRTIs + 1 NNRTI or 1 PI), once-daily DRV/r monotherapy has shown non inferior HIV RNA suppression at week 48 compared with a standard therapy of 2 NRTIs + once-daily DRV/r • A switch to once-daily DRV/r monotherapy can be considered in patients who have HIV RNA < 50 c/mL for more than 6 months on other treatments and no history of virologic failure, but wish to avoid toxicities related to other ARVs Arribas J, AIDS 2010;24:223-230 MONET

  9. MONET Study: Switch PI or NNRTI to DRV/r qd monotherapy Results: W96 outcome • Monotherapy is not noninferior with switch = failure analysis at W96 • Δ-5.8% (95% CI: -16.0% to +4.4%) • If resuppression with intensification included as success, then monotherapy is noninferior at W96 • Δ +1.4% (95% CI: -5.5% to +8.3%) HIV-1 RNA < 50 c/mL at W96, ITT, TLOVR (%) DRV/r monotherapy (N = 127) DRV/r + 2 NRTIs (N = 129) 92.1 100 90.7 80.6 80 74.8 60 40 20 0 Switch = failure Switch allowed Rieger A, et al. AIDS 2010. Abs. THLBB209 MONET

More Related